MONTRÉAL--(BUSINESS WIRE)--The organizers are pleased to announce that the Sweet Pharma Day’s 2nd edition, will be held on October 7, 2021, in a virtual format. This unique, invitation-only event is inviting young Canadian biotechs to submit their appl
First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus s
GreenGene F Now approved in China, provides more hemophilia A patients access to proven therapy YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation
- The results of the trial demonstrate the efficacy, safety and tolerability of GC5107 in patients with PI YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficac
Company Exceeds Preliminary Guidance with its Second Consecutive Quarter of Record Revenue LAS VEGAS & TORONTO--(BUSINESS WIRE)--Flower One Holdings Inc. (“Flower One” or the “Company”) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis
- The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 - LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage bi
Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations. Heritage to lead medical sales and commercialization across non-competing medical channels in Canada
Achievement of milestone and receipt of $10 million license payment from Medtronic Augmented Board of Directors and strengthened leadership team Progress on development activities to support submission of IDE application to FDA TORONTO--(BUSINESS WIRE)
DENVER--(BUSINESS WIRE)--$CBD.U #CBD--HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced
Appointed Andrew Hall, Chief Business Officer, as interim CEO, Jeremy Graff, PhD as Chief Scientific Officer, Stanley Frankel, MD and Jose Iglesias, MD as Clinical Advisors Strengthened financial position and extended cash runway with the completion
Game Changers is the first report to compile Canada’s extensive activity in alternative protein development in one place.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.